The Effects of Empagliflozin on Renal Outcomes in Post Severe Acute Kidney Injury Survivors
NCT05360615 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 147
Last updated 2025-08-17
Summary
Effects of Empagliflozin compared with placebo in post severe acute kidney injury survivors, evaluated by MAKE365.
Conditions
- Empagliflozin in Post AKI Stage 2-3
Interventions
- DRUG
-
Empagliflozin 10 MG
SGLT2 inhibitors
- DRUG
-
Placebo
Sponsors & Collaborators
-
Chulalongkorn University
lead OTHER
Principal Investigators
-
Nattachai Srisawat · Chulalongkorn University
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- QUADRUPLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2022-07-01
- Primary Completion
- 2024-06-01
- Completion
- 2026-07-01
Countries
- Thailand
Study Locations
More Related Trials
-
EMPAgliflozin in Heart Failure With PReserved Ejection Fraction and End Stage Renal Disease
NCT06249945 ·Status: RECRUITING ·Phase: PHASE4
-
meChANisms and sAfety of SGLT2 Inhibition in peRitoneal dialYsis
NCT05715814 ·Status: RECRUITING ·Phase: PHASE3
-
SGLT2 Inhibitors Prophylaxis Against Post-contrast Acute Kidney Injury in Diabetic Kidney Disease?
NCT04853615 ·Status: UNKNOWN
-
The Efficacy and Safety of Sodium-glucose Cotransporter 2 Inhibitors in Patients With Acute Kidney Disease
NCT06528405 ·Status: RECRUITING ·Phase: PHASE2
-
PROTOCOL 3: Role of the Renal Nerves in the Increase in EGP in Response to Glucosuria
NCT03168295 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy and Safety of Empagliflozin in NODAT
NCT03642184 ·Status: TERMINATED ·Phase: PHASE4
-
Evaluating Comparative Effectiveness of Empagliflozin in Type 2 Diabetes Population With and Without Chronic Kidney Disease
NCT05465317 ·Status: COMPLETED
-
Empagliflozin in Heart Failure with Reduced Ejection Fraction and End Stage Renal Disease
NCT06249932 ·Status: RECRUITING ·Phase: PHASE4
-
Studies of Empagliflozin and Its Cardiovascular, Renal and Metabolic Effects
NCT03485092 ·Status: COMPLETED ·Phase: PHASE4
-
Early Treatment With a Sodium-glucose Co-transporter 2 Inhibitor in High-risk Patients With Acute Heart Failure
NCT05392764 ·Status: RECRUITING ·Phase: PHASE3
-
Effect of Empagliflozin on Urinary Excretion of Adenosine and Osteocyte Function in Patients With Chronic Kidney Disease
NCT04961931 ·Status: UNKNOWN ·Phase: NA
-
Safety, Efficacy Evaluation of Empagliflozin Administration for Neutropenia in Glycogenosis Type 1b and G6PC3 Deficiency
NCT04138251 ·Status: UNKNOWN ·Phase: PHASE2
-
Effect of Empagliflozin on Podocyte Specific Proteins in African American Veterans With NDKD
NCT06110130 ·Status: RECRUITING ·Phase: PHASE4
-
Study of Empagliflozin in Patients With Autosomal Dominant Polycystic Kidney Disease (EMPA-PKD)
NCT06391450 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE4
-
Effect of Empagliflozin on Peritoneal and Kidney Function in End Stage Renal Disease
NCT05671991 ·Status: RECRUITING ·Phase: PHASE4
-
SGLT2 Inhibitors After Acute Kidney Injury With Indications Pilot
NCT06124924 ·Status: TERMINATED ·Phase: EARLY_PHASE1
-
Empagliflozin as a Modulator of Systemic Vascular Resistance and Cardiac Output in Patients With Type 2 Diabetes
NCT03132181 ·Status: COMPLETED ·Phase: PHASE2
-
Empagliflozin in ESKD - A Feasibility Study
NCT05687058 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Empagliflozin and Cardiac Remodelling in People Without Diabetes
NCT04461041 ·Status: COMPLETED ·Phase: PHASE4
-
Metabolic and Renal Outcomes in Cardiac Surgery Patients Receiving SGLT2 Inhibitors
NCT06825156 ·Status: COMPLETED ·Phase: PHASE4
-
Empagliflozin in Patients With Glomerulonephritis
NCT05283057 ·Status: COMPLETED ·Phase: PHASE3
-
Empagliflozin Treatment in Kidney Transplant Recipients
NCT06013865 ·Status: RECRUITING ·Phase: PHASE4
-
Effects of Empagliflozin in Reducing Oxidative Stress After Kidney Transplantation
NCT04918407 ·Status: COMPLETED ·Phase: NA
-
A Pragmatic Trial Comparing Empagliflozin and Dapagliflozin Through Cluster Randomization Embedded in the Electronic Health Record
NCT06642272 ·Status: RECRUITING ·Phase: PHASE4
-
An Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment
NCT01064414 ·Status: COMPLETED ·Phase: PHASE3